ACETO Subsidiary, Rising Pharmaceuticals, to Launch Olopatadine Hydrochloride Ophthalmic Solution
PORT WASHINGTON, N.Y., Dec. 7, 2015 (GLOBE NEWSWIRE) -- ACETO Corporation (ACET), with offices and operations in 10 countries and engaged in the marketing, sale and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, today announced that Rising Pharmaceuticals, Inc., its finished dosage form generics subsidiary, is launching Olopatadine Hydrochloride 0.1% Ophthalmic Solution, an FDA-approved generic version of Alcon Inc.'s Patanol.(R)

According to IMS Health data, U.S. market sales for Olopatadine Hydrochloride Ophthalmic Solution, which is used for the treatment of allergic conjunctivitis, were approximately $223 million for the twelve months ended September 30, 2015. The launch coincides with the expiration of patent exclusivity on the brand product and Aceto expects that six or more generic competitors will enter the market at or around the same time as Rising.